Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Research

Background:

• Lipoproteins are key endogenous nanoparticles transporting fats and cholesterol, crucial in cardiovascular health.
• Modified lipoproteins, particularly high-density lipoproteins (HDL), serve as potential nanocarriers for drugs and contrast agents.
• Reconstituted HDL (rHDL) particles, formed from lipids and apolipoprotein AI (apo-AI), can be engineered for various applications.

Purpose of the Study:

• To review synthesis techniques and physicochemical properties of rHDL nanoparticles.
• To discuss structural determinants influencing rHDL function.
• To evaluate recent advancements in pharmaceutical rHDL formulations using apo-AI or mimetic peptides for therapeutic and diagnostic applications, focusing on cardiovascular diseases.

Main Methods:

• Overview of rHDL synthesis methodologies.
• Analysis of physicochemical characteristics of rHDL nanoparticles.
• Review of studies employing apo-AI and apo-AI mimetic peptides in rHDL formulation.
• Evaluation of clinical translation prospects for rHDL in cardiovascular disease treatment and diagnosis.

Main Results:

• rHDL particles can be synthesized and engineered as effective nanocarriers.
• Physicochemical properties and structural features dictate rHDL functionality.
• Apo-AI and mimetic peptides offer versatile platforms for pharmaceutical rHDL design.
• rHDL shows promise for atherosclerosis and cardiovascular disease treatment and diagnosis.

Conclusions:

• rHDL nanoparticles represent a promising platform for drug delivery and medical diagnostics.
• Further research and development are needed to overcome challenges for clinical translation.
• rHDL holds significant potential for advancing cardiovascular disease management.